On Tuesday, Viking Therapeutics, Inc. VKTX highlighted the final results from its VOYAGE Phase 2b trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH, also referred to as metabolic dysfunction-associated steatohepatitis, MASH) at the American Association for the Study of Liver Disease.Reduction in Liver Fat Content at 52 Weeks: Patients receiving VK2809 demonstrated statistically significant reductions in liver fat at Week 12, the primary endpoint.Patients receiving VK2809 ...

Oral Late Breaker Presentation Summarizes Positive Results Including Successful Achievement of Study's Primary and Secondary EndpointsData Support VK2809's Best-in-Class Profile Highlighted by Robust Liver Fat Reductions, Histologic Results Demonstrating NASH/MASH Resolution and Fibrosis Improvement, and Promising Tolerability and SafetySAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel ...

There aren't many biotechs that are more exciting than Viking Therapeutics (VKTX -7.45%) right now. Thanks to its clinical-stage candidate for weight loss, there's a real chance that this competitor could see its shares soar for years.But that doesn't mean you should rush to buy the stock without understanding what else is going on with this stock and why it's making the changes it's making. Let's examine three things you'll need to factor into your decision if you plan on investing in Viking Therapeutics t ...

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (VKTX -7.45%), a mid-cap biotech that rose in prominence this year. The drugmaker's shares are up by nearly 200% since January.However, while many investors are excited about Viking's prospects, others worry they have already missed the boat. How much upside does a clinical-stage biotech with a market cap of $6.3 billion have? Is it too late to invest in Viking Therapeutics, or do the company's shares rem ...

Mergers and acquisitions could make a comeback with Trump headed back to Washington.The 2024 presidential election and President-elect Donald Trump is headed back to Washington. The Republican party also won control of the Senate and the House of Representatives.If Trump's previous tenure in the Oval Office is an indicator for what can be expected, there's a good chance for a less stringent regulatory environment.One of my big predictions under a Trump presidency is that mergers and acquisitions (M&A) will ...

Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.So far this year, Eli Lilly (LLY 0.54%) has been on an absolute tear and is swiftly becoming the world's most prolific pharmaceutical operation in my eyes. In addition to the unprecedented growth of its diabetes and obesity care treatments, Lilly has also secured some major wins from the Food and Drug Administration (FDA), including approval for both its Alzheimer's disease candidate and eczema drug.While it looks ...

Results to be Featured in Oral Late Breaker PresentationSAN DIEGO, Nov. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that results from the company's Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH; also ...

Viking stock has slipped more than 20% from its peak.Viking Therapeutics (VKTX -0.54%) soared to center stage earlier this year as a potentially promising player in one of today's highest-growth healthcare markets: weight loss drugs. The biotech company presented solid data for a candidate that could eventually rival blockbuster weight loss drugs from big pharma companies Eli Lilly and Novo Nordisk. And in just one trading session, the shares skyrocketed, rising more than 100%.Since then, Viking has reitera ...

All signs are pointing toward its continued success.When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the stock will go up." And while that proposition is certainly true with Viking Therapeutics, (VKTX 4.52%) there's more than one reason for why the stock is worth buying.In fact, there are at least four arguments supporting an investment, so let's take a look at each.1. It's racing closer to generating revenue for the first timeViking i ...

The company's latest presentation supports the idea that its lead program will make billions.With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (VKTX 1.44%) are a hot commodity, to say the least. And as of early November, there's one more big green flag suggesting that investors who take the plunge will be wealthier than before. Even an investment on the scale of $5,000 could see a meaningful run-up, assuming its plans to compete in the market for anti-obesity medicines com ...